[CAS NO. 263251-78-1] Tavilermide
PRODUCTS SPECIFICATIONS [263251-78-1]
DESCRIPTION [263251-78-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 580.54 |
| Molecular Formula | C24H32N6O11 |
| SMILES | O=C(O)CC[C@H](N1)C(N[C@@H](CCCCN)C(N[C@H](C(NCC(O)=O)=O)CCOC2=CC=C([N+]([O-])=O)C=C2C1=O)=O)=O |
2 Publications Citing Use of MCE
Summary
Tavilermide is a selective, partial agonist of TrkA , or a nerve growth factor (NGF) mimetic.
IC50 & Target
TrkA [1]
In Vitro
Tavilermide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye.Tavilermide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilermide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01257607 | Mimetogen Pharmaceuticals USA, Inc. |
Dry Eye
|
November 2010 | Phase 2 |
| NCT02665234 | Mimetogen Pharmaceuticals USA, Inc. |
Keratoconjunctivitis Sicca
|
January 2016 | Phase 3 |
| NCT03925727 | Mimetogen Pharmaceuticals USA, Inc. |
Keratoconjunctivitis Sicca|Dry Eye
|
March 28, 2019 | Phase 3 |
| NCT01960010 | Mimetogen Pharmaceuticals USA, Inc. |
Dry Eye Syndromes
|
October 2013 | Phase 3 |
| NCT02634853 | Mimetogen Pharmaceuticals USA, Inc. |
Keratoconjunctivitis Sicca
|
December 2015 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
NH4OH : 50 mg/mL ( 86.13 mM ; ultrasonic and adjust pH to 10 with NH4OH)
H 2 O : 2 mg/mL ( 3.45 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7225 mL | 8.6127 mL | 17.2253 mL |
| 5 mM | 0.3445 mL | 1.7225 mL | 3.4451 mL |
| 10 mM | 0.1723 mL | 0.8613 mL | 1.7225 mL |
-
1.
Add each solvent one by one: 50% PEG300 >> 50% saline
Solubility: 25 mg/mL (43.06 mM); Suspended solution; Need ultrasonic
-
2.
Add each solvent one by one: 0.5% CMC-Na /saline water
Solubility: 10 mg/mL (17.23 mM); Suspended solution; Need ultrasonic
-
3.
Add each solvent one by one: PBS
Solubility: 4.17 mg/mL (7.18 mM); Clear solution; Need ultrasonic and warming and heat to 60°C